detail bottom CFO, our Fred I'll Biofrontera's QX of top call, and everyone we positively Tirth, with our this will and and On questions us results, discussion with growth how provide will line. today's conclude and organization to update answers. you, a the thanks have an our to on impacted financial improvements Leffler, follow joining Thank many strategy and morning.
This our initiative quarter the for has strategy on company. XXXX, to continued been organization. execute we our During the to transformative of third optimize
and shifted to We costs medical reimbursement support. from training, marketing, have administration and resources sales, sales
the and this not over our medical dermatology also increased team force of on territories, grew we coverage our by hands. but size we sales bought into Furthermore, Specifically, experience to of and working care our only health our XX to XXX alongside medical education. expanded nearly X, liaison years XX%, sales
helping timing. Lastly, we sales on site team, initiated may solve our for reimbursement with an issues increased to doctors' building reimbursement, and field in-house face we they offices staff
our flow we our made been find effort This revenue of in sales commercial investment dermatologists and for organization and positive. cornerstone education becoming significant has state of the respective Ameluz-PDT. drove the towards a sales strategy is benefits the commercial continued The an have and It cash expansion year, adaptations between optimal of many our believe balance actinic growth. our organization treatment path is for ongoing we the patients growth and to about of which organization, support and this any in with crucial keratosis
the United across The our First, we following: include our States. strategy in accounts sales Ameluz commercial to keratosis U.S. for by the reach RhodoLED expansion, be our face in elements the actinic skull, lamps With the of key positioning improved medical and standard and on infrastructure. of dedicated our strategic the combination significantly treatment growing and of with the care Ameluz of the expanding
leverage our future portfolio potential complementary label to products our FDA of our opportunistically to leveraging infrastructure extensions products. Second, the and strong of commercial relationships. established third, And customer and portfolio adding approvals
have greater territories. been that from generating regions potential, we sales on Under focused have have those and higher we our shown strategy, in metropolitan successful certain consistently sales
territories. and boosted human both medical affairs support those have in capital We
Senior Director, demand and for integrated and sales as fortified recently marketing ongoing was hire Communications. response infrastructure the made the this We commercial specialized Our Strategic of the larger and for in consolidation growing organizations. into Samantha Accounts Widdicombe opportunity practices by approaches of to addition medical
needs units successful up contracts specific that very XXX% in year. from of And expectations. quarter have about and increase organizations million, Biofrontera XX,XXX have durable Ameluz This quarter last third the tube XXXX. to the large XX,XXX been third and securing we represents our contributed in quarter the drove approximately from selling a $X.X large revenue third quarter, third in of These growth which tubes to
Our driven sharp by also this Ameluz revenue in part year-over-year increase year's increase. is price
our months. facing first of company, with many costs yet higher are price in other As was QX industries, the areas increase our many we XX in
X% X, into quarter. caused dermatologists the third channelize October price Ameluz some the increase of On purchases
future, the point. stands to inflection an look we As Biofrontera at
commercial to continue well organization and market gains. our positioned share expanded generate Our is growth
field to approved an therapy the is therapy example As our growing need FDA. to drug for is Field Ameluz-PDT for and that compared AK. we PDT treating cryo, Ameluz offices an for significantly capabilities by throughout treat important in the AK of only market for onboarded share the PDT country with physician and medical general the more
for Year-to-date, our of time. XX, where the we prior trials our installed the for many increase shipped effectiveness of the advancing Innovation Ameluz at strategy, outcomes to September year BF-RhodoLED of clinical I'm itself. confident period, enhanced in a and score, our expansion, of benefits long-term a record Biofrontera's These label we our for XXX% are the stakeholders. sales heed and over Ameluz first strategic will of offices XXX that BF-RhodoLED reflecting we is including proud lamps as formulation work underscore also investments key and
This project together potential causing new a are multiple positively of also and contaminants could and patent ingredient granted, impacts to in at a to eliminates to for filed planning that formulation, research propylene components, new accumulate of glycol, an recently was that protection to for formulations exhibiting production XXXX. due U.S. have Following implement formulation with extended change profile least found Ameluz, formulation in the it's FDA formulation was we we time. and our the safety potential chemically patent this allergic with all received approval Ameluz from application certain risks Bioscience, protection. and other semi-solid in until new the over improves if updated replaced Biofrontera XXXX. our A be reacting protect stability partner, X-year This Ameluz
Let There top tolerability results extension evaluating me In our conducted portfolio growth now to Ameluz, nonrandomized were active from I turn are the while the emergent of the for demonstrating to more generally together together consistent with was A additional driver of value surface larger with R&D area open-label partners. X fewer well X with both for a the ability physicians is visits. study, U.S. capture innovation tolerated and Biofrontera and benefits place safety the office from line of for announced the treatment positive August, Phase Ameluz, treat tubes Biofrontera of label studies multi-center at we key potentially X Bioscience. information treatment of potential to with and prescribing the adverse the tubes treatment requiring and events patients tube. because taking
June study studies issues, course the an treatment, submission. With for pharmacokinetic the no required months approval potential XXXX, we additional of back is the be FDA or of expect to and have in earlier to after the X will safety These this study be by the findings and safety of which X-tube final the month. FDA FDA hear submitted from to studies the approximately by tolerability the safety
basal the a unmet announced radiation. of carcinoma BCC, treatment together BF-RhodoLED cases less more in with non-melanoma are also efficacious, medical to or invasive significant the of ionizing We BCC, without XXX need study with in for patients enrollment cell pre-malignancies therapies now for to skin is cancer the that Ameluz superficial cost-effective leading of underlying clinical all and evaluating complete Approximately U.S. III treat Phase SBCC. X/X in combination
mid-XXXX. look to Phase We III in study from results this forward sharing
this currently will physicians indication SBCC In treatment to the treatment lesions of include damaged addition areas. Ameluz-PDT damage our sun to to logical treating approved surface to neoplastic over keratosis. fields This step all of label one individual for with sun-induced skin next the Ameluz it allow the clinical lesions, is into SBCC field-directed larger for is in larger goal adding offer as
and expanding treat keratosis and a actinic for a label Regarding there demand Ameluz keratosis, large face scull. the effective to within therapy is the beyond highly actinic growing
with Phase subjects evaluating Bioscience, ongoing enrolling. study, that's tongue patients and date, the neck have body extremities, to the we XXX have aim III region. Together currently with XX an an on the use Biofrontera stratified by own dosed, of To Ameluz-PDT been enroll
to recruiting the for actively moderate of acne treatment study with Phase Ameluz. severe Lastly, II is
in a date. XXX the treatment XX options without major have that unmet of market Here, medical been and of an see, this side for approval need indication a significant Ameluz. is to Treatment substantially patients dermatologists dosed in potential current effects acne will of to the indication raise severe moderate
As second FDA-approved you topic, XEPI. FDA growth. that been our the to approved like the on prescription problematic resistance common a was for resulted infection time, we cream bacterial I and with antibiotic by against a drug, Currently, a XEPI inhibits This topical final would no known is it is has update stand where for commercialization of providing due manufacturer to product. to our very our a developments delays is aureus pyogenes. staphylococcus which Biofrontera and have the XEPI as There been skin impetigo, of some revenue in that limited to staphylococcus has with supply treatment third-party
options manufacturer, which this now developing us been including with relaunch actively the a has Ferrer, the product, of XXXX. licensor, in new allows Our potential explore a early to
financial the With to quarter. to Fred? that, the I'll details Fred over review the call turn of
